Can donor immune cells tame stem cell transplant risks?

NCT ID NCT07758218

Not yet recruiting Disease control Sponsor: University of Wisconsin, Madison Source: ClinicalTrials.gov ↗

First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time

Summary

This trial tests whether an experimental cell therapy called agenT-797 is safe for people receiving a stem cell transplant for blood cancers like leukemia or myelodysplastic syndrome. Participants get an infusion of agenT-797 about a week after their transplant. The main goal is to check for side effects and see if it helps reduce complications like graft-versus-host disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: agenT-797, an off-the-shelf cell therapy made from donor iNKT cells
What this could lead to: If safe, this could help prevent complications like graft-versus-host disease after stem cell transplants, improving recovery and survival.
What could go wrong: This is an early-phase trial with a small number of participants, so safety and effectiveness are not yet proven. There may be unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia acute myeloid leukemia chronic myelogenous leukemia, BCR-ABL1 positive Leukemia, Myelogenous, Chronic, BCR-ABL Positive lymphoid neoplasm myelodysplastic syndrome Myelodysplastic Syndromes myeloid neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA ALLOGENIC STEM CELL TRANSPLANTATION CHRONIC MYELOID LEUKEMIA LYMPHOID MALIGNANCIES MYELODYSPLASTIC SYNDROME MYELOID MALIGNANCIES

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

University of Wisconsin - Madison

Madison, Wisconsin, 53792, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.